Central nervous system (CNS) drug development continues to present unique scientific, clinical and regulatory challenges. In this podcast, Marcus Delatte, VP, Regulatory Strategy at Allucent, explores how emerging approaches, including artificial intelligence (AI), New Approach Methodologies (NAMs) and evolving regulatory thinking, could help reshape the development of new CNS therapies.
The discussion considers the opportunities presented by these innovations and what their adoption could mean for sponsors seeking to build more informed, efficient and evidence-driven development strategies.
This podcast explores
- How AI can support more efficient, informed decision-making in CNS drug development
- The growing role of new approach methodologies (NAMs) in complementing traditional pre-clinical approaches
- What regulators consider when evaluating novel scientific approaches
- Why early regulatory engagement matters when developing programs that use emerging technologies
- How sponsors can balance scientific innovation with patient safety and regulatory expectations
FAQs
CNS drug development faces complex disease biology, variable disease progression and difficulties delivering therapies across the blood–brain barrier. Selecting suitable patients, reliable biomarkers and meaningful clinical endpoints adds further complexity.
AI can analyze imaging, genetic and clinical data to help identify drug targets, explore disease progression and inform trial design. Its value depends on high-quality data, appropriate validation and expert oversight.
NAMs include human cell-based assays, organoids, organ-on-a-chip systems and computational models. These approaches can generate evidence relevant to human biology while helping reduce or replace animal testing.
Early regulatory strategy connects scientific evidence, clinical development plans and regulatory expectations. It helps sponsors identify evidence gaps, select appropriate endpoints and engage regulators on innovative approaches before making key development decisions.
AI and NAMs may help sponsors better understand disease biology, assess potential treatment effects and make more informed development decisions. Integrating these tools with scientific expertise and regulatory strategy helps ensure they address relevant questions and generate evidence suitable for its intended use.
Request a Proposal
Share This
